CS-1008 (humanized anti-DR5 antibody)

DRUG2 trials

Sponsors

Daiichi Sankyo

Conditions

LymphomaMalignanciesPancreatic Cancer

Phase 1

Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)

CompletedNCT00320827

Daiichi SankyoLymphoma, Malignancies

Target: 40Updated: 2007-09-11

Phase 2

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

CompletedNCT00521404

Daiichi SankyoPancreatic Cancer

Start: 2007-08-15End: 2010-08-20Updated: 2021-04-08